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We evaluated the percentage of hospitalizations for
acute respiratory tract infections in children <3 years of age
attributable to human metapneumovirus (HMPV) and other
respiratory viruses in a prospective study during winter and
spring 2002. We used real-time polymerase chain assays
and other conventional diagnostic methods to detect
HMPV, human respiratory syncytial virus (HRSV), and
influenza viruses in nasopharyngeal aspirates of children.
HMPV was detected in 12 (6%) of the 208 children hospi-
talized for acute respiratory tract infections, HRSV in 118
(57%), and influenza A in 49 (24%). Bronchiolitis was diag-
nosed in 8 (68%) and pneumonitis in 2 (17%) of HMPV-
infected children; of those with HRSV infection, bronchioli-
tis was diagnosed in 99 (84%) and pneumonitis in 30
(25%). None of the HMPV-infected children was admitted
to an intensive-care unit, whereas 15% of those with HRSV
or influenza A infections were admitted. HMPV is an impor-
tant cause of illness in young children with a similar,
although less severe, clinical presentation to that of HRSV. 
T
he human metapneumovirus (HMPV) is the first mem-
ber of the new Metapneumovirus genus
(Paramyxoviridae family) that infects humans (1,2). The
human respiratory syncytial virus (HRSV) belongs to a
separate genus within the same family (3). HMPV has
been recently identified in nasopharyngeal aspirates of
children and adults with acute respiratory tract infections
(ARTI) in various parts of the world (1,4–7). The clinical
syndrome of the infected children ranges from mild respi-
ratory problems to bronchiolitis and pneumonitis (1,7–9).
When reverse-transcription polymerase chain reaction
(RT-PCR) has been used, the proportion of HMPV detect-
ed in nasopharyngeal aspirate samples from children with
unexplained ARTI has varied from 1.5% to 10% (1,4,7).
However, most retrospective studies had limitations: for
example, they were small, excluded patients who tested
positive for other viruses, only superficially described the
clinical features of the disease, and lacked data on illness
severity and death. Moreover, in the absence of a control
group, these studies could not differentiate whether HMPV
was a colonizing or a pathogenic virus. More recently,
Stockton et al. identified HMPVRNAin 2.2% of 405 spec-
imens from patients with influenzalike illnesses who con-
sulted general practitioners in England, although few
swabs were collected from children <5 years of age (6).
The objectives of this study were to estimate the rela-
tive contribution of HMPV in children’s hospitalization for
ARTI and to define its clinical features and seasonal pat-
tern relative to other common respiratory viruses over a
single winter season.
Materials and Methods
Study Design 
Participants were children <3 years of age who were
hospitalized from December 15, 2001, to  April 20, 2002,
at Laval University Hospital Center in Québec City,
Québec, Canada. Case-patients were children admitted for
an ARTI (mostly bronchiolitis, pneumonitis, and laryngo-
tracheobronchitis) who had a nasopharyngeal aspirate col-
lected as part of the investigation of their illness (in this
hospital, collecting such samples is standard practice to
assess the presence of HRSV in children). The research
nurse at the microbiology laboratory that received the
nasopharyngeal aspirate specimens identified eligible
case-patients. Case-patients hospitalized twice were count-
ed as two cases. A specific questionnaire for the study was
completed at admission by a single research nurse with the
parents. At the end of the hospitalization, the children’s
charts were reviewed to collect clinical and laboratory data
by using a standardized protocol. Eligible controls were
children hospitalized for any elective surgery who had no
respiratory symptoms or fever. At admission, the nurse
obtained a signed consent from parents and collected a
nasopharyngeal aspirate (1–2 mL). The study was
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Laboratory Testing
For this study, all specimens from case-patients and
controls were tested by RT-PCR for HMPV, influenza A
and B, and HRSV. Antigen detection for HRSV was per-
formed for all case-patients immediately at admission.
Viral cultures and other antigen detection assays were per-
formed on request of the treating physician. The rest of the
specimen was then frozen at –80°C until subsequent RT-
PCR studies. 
RNA Extraction and RT-PCR Studies 
Viral RNA was extracted from 200 µL of nasopharyn-
geal aspirate specimens by using the QIAamp viral RNA
Mini Kit (QIAGEN, Inc., Mississauga, ON, Canada).
Complementary cDNA was synthesized by using 10 µLo f
eluted RNA and the Omniscript Reverse Transcriptase
(QIAGEN). Random hexamer primers (Amersham
Pharmacia Biotech, Baie d’Urfé, Québec, Canada) were
used in the RT step of all PCR assays, except for HMPV,
in which a specific primer (5′-TGGGACAAGTGAAAAT-
GTC-3′) served to synthesize HMPV cDNA. PCR assays
were designed to amplify conserved regions of influenza A
(10), influenza B (11), and HRSV (12) genes. New PCR
primers were designed for amplification of the HMPV N
(nucleoprotein) gene. The sequences of the forward and
reverse primers were respectively 5′-GAGTCTCAGTA-
CACAATTAA-3′ and 5′-GCATTTCCGAGAACAACAC-
3′. Complementary DNA was amplified for all respiratory
viruses by using a standardized RT-PCR protocol with the
LC Faststart DNA Master SYBR Green 1 Kit (Roche
Diagnostics, Laval, Québec, Canada) in a LightCycler
instrument (Roche Diagnostics). The melting curve analy-
sis program of the LightCycler was used to identify specif-
ic PCR products. Each PCR assay could detect at least 50
copies of viral target. For phylogenetic studies, nucleotide
sequences were determined from amplified HMPV F
(fusion) gene products, then analyzed by using the neigh-
bor-joining algorithm and Kimura-2 parameters (9).
Standard Viral Cultures and Antigenic Assays
Specimens were injected onto 96-well plates containing
10 cell lines (MDCK, LLC-MK2, Hep-2, human foreskin
fibroblast, Vero, mink lung, A-549, rhabdomyosarcoma,
293, and HT-29) and then incubated for 21 days. Apositive
cytopathic effect was confirmed by immunofluorescence
testing with monoclonal antibodies or by RT-PCR
(HMPV) (9). Detection of HRSV and influenza antigens
was performed directly on nasopharyngeal aspirate sam-
ples by using commercially available immunoenzymatic
assays (RSV TestPack, Abbott Laboratories, Abbott Park,
IL; Directigen Flu A + B, Becton Dickinson Microbiology
Systems, Sparks, MD). Viral antigens for adenoviruses and
parainfluenza viruses 1–3 were sought in specimens by an
immunofluorescence method with specific monoclonal
antibodies (9).
HMPV in the General Population 
To further assess the seasonal distribution, affected age
groups, and frequency of HMPV, we compared data from
this study with data from the general population using pos-
itive viral cultures reported by our regional virology diag-
nostic laboratory, the only one performing viral cultures
for the Québec City area (population 600,000). Isolation of
HMPV was achieved by observing typical cytopathic
effect on LLC-MK2 cells, followed by PCR confirmation
on infected cell culture supernatants (9).
Statistical Analyses
The Wilcoxon nonparametric test was used to compare
the age distribution of case-patients and controls and peri-
od of hospitalization. The proportion of cases and controls
with HMPV infections and the clinical features of children
infected with HMPV versus those infected with other res-
piratory viruses were compared by the chi-square test or
the Fisher exact test. Analyses were performed by using
SAS software version 8.02 (SAS Institute, Inc., Cary, NC).
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Figure 1. Age at admission of children hospitalized for acute respi-
ratory tract infections caused by human metapneumovirus
(HMPV) (A), human respiratory syncytial virus (HRSV) (B), and
influenza A (C) as well as for the whole study population (D).Results
Study Population and Viral Etiologic Agents 
The study population included 208 hospitalized case-
patients with ARTI (including 8 children who were admit-
ted twice) and 51 children who served as controls. The age
distribution of case-patients and controls is presented in
Figure 1. Infants <3 months of age were most likely to be
hospitalized, and the rate of hospitalizations steadily
decreased in children >3 months. The mean age was slight-
ly younger for case-patients than for controls (mean 9
months vs. 12 months, Wilcoxon test p=0.06). Among
cases with ARTI, 56% were male as were 57% of controls
(p=0.88). The date of hospitalization was similar for case-
patients and controls (p=0.84) (Figure 2). Most children
(90%) had no underlying medical conditions at admission. 
Anasopharyngeal aspirate sample was taken for all 208
case-patients and 51 controls.  For case-patients, the mean
delay between the onset of symptoms and collection of
nasopharyngeal aspirates was 6 days (median 4 days)
(Table 1). This delay did not differ for the different virus-
es detected. Samples from all 208 case-patients were test-
ed by PCR for HMPV, HRSV, and influenza A and B; 204
samples were tested for HRSV antigen; 172 were assayed
for other viral antigens; and 145 were tested by viral cul-
ture for the whole panel of respiratory viruses (as ordered
by the treating physician). At least one respiratory virus
was detected by one of the above methods in 164 (78.8%)
cases, whereas none was detected in 44 (21.2%).
Combining these diagnostic techniques, 12 cases (5.8%)
were positive for HMPV, 118 (56.7%) for HRSV, 49
(23.6%) for influenza A, and none for influenza B (Table
1). In contrast, a virus was not detected by PCR in any of
the control samples (p=0.067 for HMPV, one-sided Fisher
exact test). PCR testing was not done for adenoviruses and
parainfluenza viruses, but these viruses were respectively
found in 6/145 (4.1%) and 2/145 (1.3%) of tested case-
patients by the use of viral cultures or antigenic assays.
Single virus infections occurred in 141 (86.0%) of the 164
positive case-patients, and mixed infection was found in
23 (14.0%). Two of the 12 HMPV infections were mixed
(HMPV-influenza and HMPV-HRSV). The other combi-
nations were HRSV–influenza A (18 cases), HRSV-aden-
ovirus (2), and influenza A–adenovirus (1).
Among the 208 case-patients tested by PCR for HMPV,
HRSV, and influenza A and B viruses, the positivity rates
were 5.8%, 51.0%, 21.6%, and 0%, respectively (Table 1).
In addition, 16 other case-patients had one of these four
respiratory viruses identified only by culture (one influen-
za A and one HRSV), only by an antigen detection test
(nine HRSV and three influenza A), or by both culture and
antigen detection test (two HRSV). Among the eight chil-
dren who were hospitalized twice, none had the same viral
infection at both admissions. The specific combinations
observed were HMPV-HRSV (two), HMPV–no virus
(one), HRSV–no virus (two), HRSV-influenza (two), no
virus–no virus (one). 
The biweekly distribution of cases with respiratory
tract viruses is shown in Figure 2. HRSV and influenza A
infections occurred predominantly from January to March,
whereas HMPV infections occurred mostly in March and
April. The proportion of children with virologically con-
firmed respiratory tract infections decreased after
February.
Clinical Features of Cases
Given the small number of HMPV cases, the results
only suggest trends, as no statistical comparison reached
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Figure 2. Biweekly distribution of virologically confirmed cases with
acute respiratory tract infections and their controls.
Table 1. Type of laboratory confirmation by type of infection 
HMPV
a  HRSV  Influenza A  Adenovirus  PIV 2 
Laboratory test 
No. 
tests 
Positive 
(%) 
No. 
tests 
Positive 
(%) 
No. 
tests 
Positive 
(%) 
No. 
tests 
Positive 
(%) 
Test 
done 
Positive 
(%) 
PCR  208  12 (5.8)  208  106 (51.0)  208  45 (21.6)  NA  NA  NA  NA 
Culture  145  2 (1.4)  145  37 (25.5)  145  10 (6.9)  145  6 (4.1)  145  1 (0.7%) 
Antigen detection  NA  NA  204  94 (46.1)  172  19 (11.0)  81  1 (1.2)  76  1 (1.3%) 
Total (+) in at least one test  12 (5.8%)  118 (56.7)  49 (23.6)  6 (4.1)  2 (1.3%) 
Delay between onset of symptoms 
and NPA, days; mean/median  6.3/5.0  5.2/4.0  8.7/5.0  6.0/6.5  3.0/3.0 
aHMPV, human metapneumovirus; HRSV, human respiratory syncytial virus; PIV, parainfluenza virus; NPA, nasopharyngeal aspirate; PCR, polymerase chain reaction; 
NA, not applicable. significance. The peak age for hospitalized HMPV infec-
tion was 3–5 months, whereas it was 0–2 months for
HRSV infection (Figure 1). Influenza A virus infection
occurred evenly throughout the first year of life. The peak
age for mixed infection was 6–11 months; the frequency of
such infections decreased thereafter. Gender was distrib-
uted evenly within each virus group, but more males
(70%) had mixed viral infections. Most (75% with HMPV,
93% with HRSV, 90% with influenza A virus infection) of
the children in the etiologic agent groups had no underly-
ing medical conditions. Three (25%) children with HMPV
infection had a cardiac disorder, including one child with
multiple medical problems.
Signs and symptoms recorded with the different respi-
ratory viruses were similar (Table 2). The median duration
of hospitalization was similar for HMPV, HRSV, and
influenza A viruses being respectively 4.5, 5.0, and 4.0
days (p=0.85). Of note, four (33.3%) HMPV-infected chil-
dren were hospitalized for >7 days, including one child
with underlying conditions. None of the children with
HMPV infection was admitted to the intensive-care unit
(ICU) in contrast to 15% (p=0.22) with HRSV and 16%
(p=0.34) with influenza A infections. None of the children
in this study died. The duration of the hospitalization for
children with no detectable virus was shorter than that for
children with single or mixed infection (Wilcoxon test, p
<0.001). Two thirds of the children were given antibiotics
during their hospitalization, although almost none had
specimens collected for bacterial cultures.
At hospital discharge, a final diagnosis of bronchiolitis
was given to 67% of children with HMPV, 84% with
HRSV, and 51% with influenza A (p <0.001) (Table 3).
Otitis media occurred in about half of the children with
HMPV, HRSV, and influenza A virus infections.
Pneumonitis was less frequently diagnosed in children
with HMPV compared to those with HRSV or influenza A
(17%, 25%, and 37%; p=0.22). Definitive clinical diag-
noses were similar with single and mixed infections.
HMPV in the General Population 
The regional virology laboratory received 1,505 respi-
ratory specimens for viral culture from January 1 to June
30, 2002. In total, 36 (including 2 study participants) or
2.9% were positive for HMPV: 24 (67%) in children <2
years of age, 5 (14%) in those 2 to 4 years of age, 4
(11.1%) in adults 30–49 years of age, and 3 (8%) in those
>70 years of age. No clinical information was available
from these cases. Most isolates (81%) were recovered
over a 2-month period (from March 23 to May 18 ). When
the seasonal distributions of HMPV in hospitalized chil-
dren (study population) and in the general population
were compared, we found that  the study did not cover the
entire HMPV season and that it had been stopped just
after the peak time of HMPV transmission (April 6–20)
(Figure 3).
Phylogenetic Analyses of HMPV Strains
The 12 HMPV strains detected in hospitalized children
(study population) clearly clustered into two F lineages as
previously reported (1,5,9); nine strains belonged to group
1 (which includes the prototype strain from the
Netherlands, GenBank accession no. af371337) and three
to group 2 (Figure 4). Seven of the nine group 1 strains had
identical F gene sequences although they were not tempo-
rally related. At the nucleotide level, similarity between
groups was 84% to 85%, compared to 98% to 100% with-
in group 1 and 93% to 99% similarity within group 2,
respectively. 
Discussion
Our prospective study has shown important clinical and
epidemiologic features of HMPV infection. First, our data
indicate that HMPV is really a respiratory pathogen with
an epidemic behavior. Second, we found that HMPV sub-
stantially contributes to ARTI that leads to children’s hos-
pitalization, although in smaller proportion than HRSV
and influenza viruses. Although all specimens from this
study were tested by PCR, only a subset was studied by
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Table 2. Signs and symptoms by type of viral infection 
Signs and symptoms 
% HMPV
a, 
n=12 
% HRSV, 
n=118 
% Influenza A, 
n=49 
% Single virus, 
n=141 
% Multiple 
viruses, n=23 
% No virus 
detected, n=44 
% Total, 
n=208 
Fever  67  57  78  60  74  57  61 
Cough  100  99  96  98  100  90  97 
Rhinorrhea  92  91  84  87  96  96  90 
Retractions  92  95  82  89  96  89  89 
Wheezing  83  65  57  59  83  71  64 
Lacrymation  25  31  31  33  26  25  30 
Diarrhea  8  17  27  17  22  23  19 
Vomiting  25  8  10  7  17  2  7 
Other  0  26  18  23  17  21  22 
aHMPV, human metapneumovirus; HRSV, human respiratory syncytial virus. Given the small number of HMPV cases, the results only suggest trends, as no statistical 
comparison reached significance. viral culture. However, such incomplete virologic testing
should not have significantly affected the rate of HMPV
infection as evidenced by the absence of additional cases
detected by culture. Third, the clinical features associated
with HMPV were found to be similar to those of HRSV.
Finally, our results suggest that the seasonal pattern of
HMPV infection in children may differ from that of HRSV
and influenza viruses although additional studies are need-
ed because of our relatively short period of observation.
Recent studies by our group (8,9) and others (1,4,6,7)
have suggested that HMPV should be added to the list of
human respiratory viral pathogens (13–18) affecting main-
ly children, but also other age groups as well. Although the
difference in HMPV positivity between our 208 case-
patients and 51 controls was not statistically significant
(p=0.067), the absence of other respiratory viruses such as
HRSV and influenza viruses in 83% of the HMPV-infect-
ed children and the severity of the symptoms (bronchioli-
tis, pneumonitis, or both) suggest that HMPV is a patho-
genic respiratory virus. The absence of underlying medical
conditions in 75% of the HMPV-infected children further
illustrates the pathogenicity of HMPV. The use of PCR
was particularly advantageous for HMPV detection
because this virus is  fastidious and difficult to grow in
most cell lines (9); in addition, rapid antigenic detection
tests are not currently available.
Our prospective study provides for the first time an esti-
mate of the proportion of ARTI hospitalizations attributa-
ble to HMPV in a well-defined pediatric population. From
December 15to April 20, 2002, HMPV was detected in 12
(6%) of 208 children <3 years of age who were hospital-
ized for respiratory tract infections. This probably underes-
timates the real impact of this virus because our hospital-
ization study was stopped before the end of HMPV trans-
mission in the community. However, the percentage of
hospitalizations caused by HMPV during the study period
was much smaller than that attributable to HRSV or
influenza A. Our data are comparable to those of a recent
small study from Finland in which HMPV was detected in
8% of children (age range, 4 months to 13.5 years) admit-
ted for acute wheezing (7).
Our study found that HMPV disease cannot be distin-
guished from HRSV and influenza A on clinical findings.
However, HMPV disease tended to be somewhat less
severe with fewer cases of pneumonia, no admission in the
ICU, and a greater proportion of underlying diseases
(25%) among infected patients compared with <10% for
HRSV or influenza. Nevertheless, HMPV infection was
associated with a substantial clinical and economic impact
as shown by a median hospital stay of 4.5 days and by the
observation that one-third of HMPV-infected case-patients
were hospitalized for >7 days. 
A small serologic study from the Netherlands showed
that all children >5 years of age had HMPV antibodies,
which suggests a high level of transmission (1). While our
study data were limited to children <3 years of age, they
suggest that illness caused by HMPV is greatest in children
<2 years of age because they represented 10 (83%) of our
12 hospitalized case-patients and 24 (66%) of the 36
HMPV isolates recovered in our diagnostic virology labo-
ratory. This finding suggests that, similar to other paramyx-
oviruses such as HRSV, the most severe HMPV infections
occur through primary infection in young children. In con-
trast to HRSV, which peaked during the first 2 months of
life, HMPV hospitalizations seem to peak in children at a
slightly older age, i.e., between the third and fifth month of
life. However, given the small number of HMPVcases, this
observation needs to be confirmed in a larger study. Should
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Table 3. Definitive clinical diagnoses by type of viral infection 
Complication 
% HMPV,
a 
n=12
 
% HRSV, 
n=118 
% Influenza 
A, n=49 
% Single 
virus, n=141 
% Multiple 
viruses, n=23 
% No virus detected, 
n=44 
% Total, 
n=208 
Bronchiolitis  67  84  51  70  83  57  68 
Pneumonia  17  25  37  28  30  27  28 
Laryngotracheobronchitis  0  10  12  8  17  5  8 
Otitis  50  59  55  55  65  55  56 
Sinusitis  0  3  6  1  9  2  2 
Pharyngitis  0  1  0  1  0  5  2 
Flu syndrome  0  2  0  1  0  9  3 
Other  8  3  6  6  0  11  7 
aHMPV, human metapneumovirus; HRSV, human respiratory syncytial virus. Given the small number of HMPV cases, the results only suggest trends, as no statistical 
comparison reached significance. 
Figure 3. Biweekly distribution of virologically confirmed human
metapneumovirus (HMPV) cases from the prospective pediatric
study (study group) and from the general population as retrospec-
tively identified in the Québec City Regional Virology Laboratory
(RVL).the same trend be observed, this difference may depend on
a longer persistence of maternal antibodies or a less effi-
cient transmission mode in the case of HMPV. Both
hypotheses would require additional studies.
During the 4-week period from mid-March to mid-
April, HMPV infections clustered (11/12 cases) and were
associated with 18.9% of all hospitalizations for ARTI in
children at our institution. These findings contrast with
those for HRSV and influenza A infections, which
occurred mostly in January and February. On the basis of
passive surveillance data from our regional virology labo-
ratory, the peak time of HMPV transmission in the com-
munity occurred between April 6 and 20, 2002, and contin-
ued beyond the conclusion of our study in hospitalized
children until the end of May. Although incomplete, such
data suggest that seasonal outbreaks of HMPV may differ
from those of other common respiratory viruses.
As described for HRSV (12), several strains of HMPV
circulated during a very brief period (1 month) in our study
area. The HMPV strains segregated into two F subgroups,
in agreement with previous studies (1,5,9), although one
strain clearly predominated, accounting for 58.3% of all
infections. Because of the small number of HMPV strains
belonging to one of the F subgroup, we did not attempt to
correlate HMPV genotype with clinical outcome. Such
viral heterogeneity may allow multiple reinfections
throughout life, especially in elderly persons and immuno-
compromised patients, as we previously reported (8,9).
In conclusion, our study supports the concept of the
epidemic nature of HMPV infection and its role as a sig-
nificant pathogen in severe ARTI of children. Year-long
active surveillance studies on consecutive years and in dif-
ferent geographic regions are needed to better define the
epidemiology of HMPV.
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